News

CURE8h

Investigating Personalized Vaccine Use in Kidney Cancer Care

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...
The Manila Times16h

Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

PD-1 Inhibitor Drugs Market To Reach USD 201.5 Bn By 2035, Expanding At 15.5% CAGR TMR Analysis

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...
Zacks Small Cap Research on MSN15h

AEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month

AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...
Dermatology Advisor14h

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43 ...